Yanbu National Petrochemical Co.





Accelerated Recovery for YANSAB due to Impressive Production Efficiencies.

Yanbu National Petrochemical Co. (YANSAB), showed a significantly strong performance during Q1 2021, with sales growth of 25% compared to Q4 2020. Despite plants closure and higher feedstock prices, the company still managed to report strong net income, due to higher prices obtained, improved volumetric sales and high other income posted for the quarter. We believe that gradual improvement will continue FY2021e, as prices stabilize. Meanwhile, positive longterm outlook on the back of pick-up in economic activities post vaccine rollout.

YANSAB was able to outperform the previous market consensus, with revenues of SAR1,723mn in Q1 2021 representing a Y-o-Y growth of 44.2% (25.0% Qo-O). The company's significantly high revenues (highest level of quarterly revenues in 2 years), came despite maintenance in its Ethylene Glycol and Olefins plants for 25 days and 10 days; respectively. The company's production efficiencies were key in its strong performance during the quarter, aided by the increase in average prices for most of its key products in addition to healthier demand that led to higher volumetric sales.

The Asian average prices of MEG, YANSAB's key product, increased around 13.5% Y-o-Y (27.2% Q-o-Q) reaching its highest level since 2019. Moreover, HDPE prices increased by 6.5% Q-o-Q, while PP increased by 11.6%. Finally, Propane average prices increased by 37.2% Q-o-Q (USD535/MT).

COGS for the quarter were at SAR1,192mn in Q1 2021, an increase by 19.7% Y-o-Y (31.9% Q-o-Q), mainly due to 28.8% Q-o-Q increase in Propane-HDPE costs and 7.8% Q-o-Q increase in Propane-MEG costs. However, it is worth noting that during the quarter the company endured impairment costs of SAR64mn in addition to plant maintenance costs and a general increase in feedstock costs. That being said, Gross margin for the quarter stood at 30.8% which is a massive improvement compared to 16.7% reported form Q1 2021, however, it's a slight drop from 34.5% reported for O4 2020.

YANSAB reported operating expenses of SAR118.0, a 21.8% Y-o-Y growth (13.6% Q-o-Q. the increase in operating expenses is associated to the cost of the strong sales during the quarter. Operating profit margin stood at 24.0% for Q1 2021, compared to only 8.6% in Q1 2020 (26.9% in Q4 2020).

Finally, YANSAB posted net income of SAR420mn in Q1 2021 compared to SAR104.5mn in Q1 2020, representing an increase of 302.4% Y-o-Y (26.3% O-o-O). The impressive net income for the period was due to strong revenues in addition to higher than usual other income. Accordingly, YANSAB recorded highest net margin since Q1 2019, of 24.4% in Q1 2021 compared to 8.7% in Q1 2020 and 24.1% in Q4 2020.

YANSAB's production efficiencies during the quarter, despite the preventative maintenance on two of its plants, significantly accelerated the company's recovery. Coupled with the improved prices, and healthier demand, the company is overlooking gradual improvement towards the end of FY2021e. On a macro-level, the vaccine rollout is bound to accelerate the pick-up in global economic activities, which should further improve demand. However, we believe that on the short term, prices will stabilize on the current levels.

We update our 52 weeks target price SAR75.5/share with a Neutral recommendation.

27 April 2021

Recommendation	Neutral
Previous Recommendation	Neutral
Current Price (26-04-2021)	SAR73.2
Previous Target Price	SAR75.5
Upside/ (Downside)	3.1%
Shariah Compliance	Pass


Key Financial Ratios

Ratio	Q1 2021	Q4 2020	Q1 2020
Revenue Growth	25.0%	-4.3%	-19.4%
Gross Margin	30.8%	34.5%	16.7%
EBIT Margin	24.0%	26.9%	8.6%
Net Margin	24.4%	24.1%	8.7%

Key Financial Results (Q1 2021)



Share Price Performance





Yanbu National Petrochemical Co.



	_ \	-		4 .	
	_ \		lua	1	on
		. a.	IUA		w

	2021 E	2022 F	2023 F	2024 F	2025 F	2026 F			
EBITDA	2,303	2,473	2,639	2,746	2,856	2,968			
Operating CF	2,122	2,303	2,526	2,702	2,773	2,884			
Capex	(471)	(503)	(531)	(547)	(564)	(581)			
FCFF	1,651	1,801	1,995	2,155	2,210	2,303			
Stub Period (FCF to be discounted)	1,244	1,801	1,995	2,155	2,210	2,303			
PV (FCFF)	1,175	1,576	1,619	1,621	1,541	1,489			
WACC	7.9%								
Perpetuity Growth	3.0%								
PV-FCFF	9,020	We have valued	YANSAB using Do	CF and multiple	s approaches,	considerir			
PV-TV	31,445	a cost of equity is equal to 7.9% (based on a risk-free rate of 2.7%, mar							
Net Debt	(127)	risk premium 7.0	0%, Beta of 0.75	•					
Less: End of services benefits	(888)	Based on the I	OCF valuation, tl	ne fair price c	of YANSAB sh	are price			
Add: Investments	3,015	SAR75.5, which	is higher than the	e traded value	by 3.1%.				
Intrinsic Values	42,466								
Shares Outstanding	562.5								
Equity value per share	75.5								
CMP (26-04-2021)	73.2								
Upside / (Downside %)	3.1%								
•									

Financial Ratios	2019 A	2020 A	2021 F	2022 F	2023 F	2024 F	2025 F	2026 F
Return on Average Assets (%)	5.9%	3.8%	6.8%	8.0%	9.3%	10.3%	11.5%	12.9%
Return on Average Equity (%)	6.5%	4.4%	7.9%	9.3%	10.8%	12.1%	13.7%	15.4%
Earnings Before Zakat Margin (%)	20.2%	16.2%	21.6%	23.1%	24.6%	25.8%	27.1%	28.5%
Net Income Margin (%)	18.0%	13.5%	19.5%	20.8%	22.2%	23.2%	24.4%	25.7%
Revenue Growth (%)	-20.5%	-17.0%	18.5%	6.2%	5.8%	3.1%	3.0%	3.0%
EPS	1.9	1.2	2.1	2.3	2.6	2.9	3.1	3.3
Income Statement	2019 A	2020 A	2021 F	2022 F	2023 F	2024 F	2025 F	2026 F
Revenue from Contracts with Customers	6,065	5,035	5,968	6,338	6,705	6,909	7,119	7,333
Cost of Revenue	(4,567)	(3,946)	(4,381)	(4,564)	(4,727)	(4,791)	(4,845)	(4,889)
Gross Profit	1,498	1,089	1,586	1,774	1,977	2,118	2,274	2,444
SG&A Expenses	(402)	(361)	(398)	(416)	(439)	(452)	(466)	(480)
Income from Main Operations	1,096	728	1,188	1,358	1,538	1,666	1,808	1,964
Net Income for The Period	1,090	678	1,163	1,320	1,487	1,605	1,738	1,881
Balance Sheet	2019 A	2020 A	2021 F	2022 F	2023 F	2024 F	2025 F	2026 F
Total Current Assets	5,843	5,938	6,168	6,412	6,701	6,929	7,114	7,257
Total Non-Current Assets	12,228	11,402	10,628	9,869	9,133	8,422	7,745	7,113
Total Assets	18,070	17,340	16,796	16,281	15,834	15,351	14,859	14,371
Total Current Liabilities	1,153	1,339	1,314	1,299	1,326	1,339	1,352	1,365
Total Non-Current Liabilities	775	1,015	1,022	1,029	1,037	1,045	1,052	1,060
Total Liabilities	1,928	2,354	2,336	2,328	2,363	2,384	2,405	2,425
Total Liabilities and Equity	18,070	17.340	16.796	16,281	15,834	15.351	14.859	14.371

Guide to Ratings and Disclaimer

Guide to Ratings

Buy	An upside potential of more than 20% in 52-week period
Overweight	An upside Potential of more than 10% in 52-week period
Neutral	Will stay in the range of it value (up/down 10%) in a 52-week period
Underweight	A downside potential of more than 10% in 52-week period
Sell	A downside potential of more than 20% in 52-week period

Itqan Capital

Al Zahraa District, Al Zahraa Commercial Center, PO Box 8021, Jeddah 21482, Kingdom of Saudi Arabia

Tel: 966 12 263 8787 Fax: 966 12 263 8789 info@itqancapital.com www.itqancapital.com

Disclaimer

This research document has been prepared by Itqan Capital Company ("Itqan Capital"), Saudi Arabia. It has been prepared for the general use of Itgan Capital's clients and may not be redistributed, retransmitted or disclosed, in whole or in part, or in any form or manner, without the express written consent of Itqan Capital. Receipt and review of this research document constitute your agreement not to redistribute, retransmit, or disclose to others the contents, opinions, conclusion, or information contained in this document prior to public disclosure of such information by Itqan Capital. The information contained was obtained from various public sources believed to be reliable, but we do not guarantee its accuracy. Itgan Capital makes no representations or warranties (express or implied) regarding the data and information provided and Itgan Capital does not represent that the information content of this document is complete, or free from any error, not misleading, or fit for any particular purpose. This research document provides general information only. Neither the information nor any opinion expressed constitutes an offer or an invitation to make an offer, to buy or sell any securities or other investment products related to such securities or investments. It is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person who may receive this document. Investors should seek financial, legal or tax advice regarding the appropriateness of investing in any securities, other investment or investment strategies discussed or recommended in this document and should understand that statements regarding future prospects may not be realized. Investors should note that income from such securities or other investments, if any, may fluctuate and that the price or value of such securities and investments may rise or fall. Fluctuations in exchange rates could have adverse effects on the value of or price of, or income derived from, certain investments. Accordingly, investors may receive back less than originally invested. Itgan Capital or its officers or one or more of its affiliates (including research analysts) may have a financial interest in securities of the issuer(s) or related investments, including long or short positions in securities, warrants, futures, options, derivatives, or other financial instruments. Itgan Capital or its affiliates may from time to time perform investment banking or other services for, solicit investment banking or other business from, any company mentioned in this research document. Itqan Capital, together with its affiliates and employees, shall not be liable for any direct, indirect or consequential loss or damages that may arise, directly or indirectly, from any use of the information contained in this research document. This research document and any recommendations contained are subject to change without prior notice. Itgan Capital assumes no responsibility to update the information in this research document. Neither the whole nor any part of this research document may be altered, duplicated, transmitted or distributed in any form or by any means. This research document is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or which would subject Itqan Capital or any of its affiliates to any registration or licensing requirement within such jurisdiction.

Itqan Capital is licensed by the Saudi Arabian Capital Market Authority, License No.07058-37 and CR No.4030167335